Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

The US Military Commitment to Vaccine Development: A Century of Successes and Challenges.

Ratto-Kim S, Yoon IK, Paris RM, Excler JL, Kim JH, O'Connell RJ.

Front Immunol. 2018 Jun 21;9:1397. doi: 10.3389/fimmu.2018.01397. eCollection 2018. Review.

2.

Lower Baseline Germinal Center Activity and Preserved Th1 Immunity Are Associated With Hepatitis B Vaccine Response in Treated HIV Infection.

Paris RM, Milagres LG, Moysi E, Okulicz JF, Agan BK, Ganesan A, Petrovas C, Koup RA.

Pathog Immun. 2017;2(1):66-88. doi: 10.20411/pai.v2i1.175. Epub 2017 Mar 14.

3.

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.

Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, Kathcart AK, Hauns KD, Komisar JL, Qabar AN, Davidson SA, Dutta S, Griffith ME, Magee CD, Wojnarski M, Livezey JR, Kress AT, Waterman PE, Jongert E, Wille-Reece U, Volkmuth W, Emerling D, Robinson WH, Lievens M, Morelle D, Lee CK, Yassin-Rajkumar B, Weltzin R, Cohen J, Paris RM, Waters NC, Birkett AJ, Kaslow DC, Ballou WR, Ockenhouse CF, Vekemans J.

J Infect Dis. 2016 Sep 1;214(5):762-71. doi: 10.1093/infdis/jiw237. Epub 2016 Jun 13.

PMID:
27296848
4.

Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression.

Paris RM, Petrovas C, Ferrando-Martinez S, Moysi E, Boswell KL, Archer E, Yamamoto T, Ambrozak D, Casazza JP, Haubrich R, Connors M, Ake J, Kim JH, Koup RA.

PLoS One. 2015 Dec 17;10(12):e0144767. doi: 10.1371/journal.pone.0144767. eCollection 2015.

5.

HLA Class I Alleles Associated with Mortality in Thai Military Recruits with HIV-1 CRF01_AE Infection.

Gandhi RT, Bosch RJ, Rangsin R, Chuenchitra T, Sirisopana N, Kim JH, Robb ML, Vejbaesya S, Paris RM, Nelson KE.

AIDS Res Hum Retroviruses. 2016 Jan;32(1):44-9. doi: 10.1089/aid.2015.0120. Epub 2015 Sep 18.

6.

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders.

Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP, McElrath MJ, O'Connell RJ, Paris RM, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, Robb ML, Michael NL, Mullins JI, Kim JH, Gilbert PB, Rolland M.

Nat Med. 2015 Oct;21(10):1139-41. doi: 10.1038/nm.3932. Epub 2015 Aug 31.

7.

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.

Karasavvas N, Karnasuta C, Savadsuk H, Madnote S, Inthawong D, Chantakulkij S, Rittiroongrad S, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Siriyanon V, Andrews CA, Barnett SW, Tartaglia J, Sinangil F, Francis DP, Robb ML, Michael NL, Ngauy V, de Souza MS, Paris RM, Excler JL, Kim JH, O'Connell RJ; MOPH-TAVEG Collaboration.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1178-86. doi: 10.1089/AID.2015.0034. Epub 2015 Sep 9.

8.

Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.

Vuong C, Xie LH, Potter BM, Zhang J, Zhang P, Duan D, Nolan CK, Sciotti RJ, Zottig VE, Nanayakkara NP, Tekwani BL, Walker LA, Smith PL, Paris RM, Read LT, Li Q, Pybus BS, Sousa JC, Reichard GA, Smith B, Marcsisin SR.

Antimicrob Agents Chemother. 2015 Jul;59(7):3864-9. doi: 10.1128/AAC.00343-15. Epub 2015 Apr 13.

9.

Differential CYP 2D6 metabolism alters primaquine pharmacokinetics.

Potter BM, Xie LH, Vuong C, Zhang J, Zhang P, Duan D, Luong TL, Bandara Herath HM, Dhammika Nanayakkara NP, Tekwani BL, Walker LA, Nolan CK, Sciotti RJ, Zottig VE, Smith PL, Paris RM, Read LT, Li Q, Pybus BS, Sousa JC, Reichard GA, Marcsisin SR.

Antimicrob Agents Chemother. 2015 Apr;59(4):2380-7. doi: 10.1128/AAC.00015-15. Epub 2015 Feb 2.

10.

Use of dried blood spots for HIV-1 genotyping in Southeast Asia: Thailand experience.

Rutvisuttinunt W, Arroyo MA, Assawadarachai V, Poltavee K, McCutchan FE, Tovanabutra S, Kijak G, Kim JH, Paris RM, de Souza M.

Southeast Asian J Trop Med Public Health. 2012 Mar;43(2):333-9.

PMID:
23082585
11.

Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.

Rerks-Ngarm S, Paris RM, Chunsutthiwat S, Premsri N, Namwat C, Bowonwatanuwong C, Li SS, Kaewkungkal J, Trichavaroj R, Churikanont N, de Souza MS, Andrews C, Francis D, Adams E, Flores J, Gurunathan S, Tartaglia J, O'Connell RJ, Eamsila C, Nitayaphan S, Ngauy V, Thongcharoen P, Kunasol P, Michael NL, Robb ML, Gilbert PB, Kim JH.

J Infect Dis. 2013 Apr 15;207(8):1195-205. doi: 10.1093/infdis/jis478. Epub 2012 Jul 26.

PMID:
22837492
12.

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, Khamboonruang C, Thongcharoen P, Morgan P, Benenson M, Paris RM, Chiu J, Adams E, Francis D, Gurunathan S, Tartaglia J, Gilbert P, Stablein D, Michael NL, Kim JH.

Lancet Infect Dis. 2012 Jul;12(7):531-7. doi: 10.1016/S1473-3099(12)70088-9. Epub 2012 May 30.

13.

Enhanced U.S. Army HIV diagnostic algorithm used to diagnose acute HIV infection in a deployed soldier.

Hakre S, Paris RM, Brian JE, Malia J, Sanders-Buell EE, Tovanabutra S, Sleigh BC, Cook JE, Michael NL, Scott PT, Deuter DR, Cersovsky SB, Peel SA.

Mil Med. 2012 May;177(5):609-13.

PMID:
22645891
14.

Two unique recombinant forms identified in incident HIV type 1 infections in Thai blood donors.

Rutvisuttinunt W, Sirivichayakul S, Oota S, Assawadarachai V, Poltavee K, Savadsuk H, Pattanachaiwit S, Chaemchuen S, Arroyo MA, Paris RM, Michael NL, Kim JH, Ruxrungtham K, de Souza M, Phanuphak P, Tovanabutra S.

AIDS Res Hum Retroviruses. 2012 Dec;28(12):1703-11. doi: 10.1089/AID.2011.0339. Epub 2012 Jun 25.

PMID:
22587412
15.

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH; Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators.

J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756. Epub 2012 Apr 23.

16.

Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).

McLinden RJ, Paris RM, Polonis VR, Close NC, Su Z, Shikuma CM, Margolis DM, Kim JH.

AIDS. 2012 Jan 2;26(1):1-9. doi: 10.1097/QAD.0b013e32834d606e.

PMID:
21971356
17.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA.

PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.

18.

Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.

Paris RM, Kim JH, Robb ML, Michael NL.

Expert Rev Vaccines. 2010 Sep;9(9):1055-69. doi: 10.1586/erv.10.106. Review.

PMID:
20822348
19.

A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, Karnasuta C, Polonis VR, Baglyos L, Habib RE, Gurunathan S, Barnett S, Brown AE, Birx DL, McNeil JG, Kim JH; Thai AIDS Vaccine Evaluation Group.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):48-55.

PMID:
17909315
20.

"Strange things I have in head": evidence of prion disease in Shakespeare's Macbeth.

Norton SA, Paris RM, Wonderlich KJ.

Clin Infect Dis. 2006 Jan 15;42(2):299-302. No abstract available.

PMID:
16355346
21.

Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.

Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Brown AE, Gurunathan S, Tartaglia J, Heyward WL, McNeil JG, Birx DL, de Souza MS; Thai AIDS Vaccine Evaluation Group, Thailand.

Vaccine. 2005 Mar 31;23(19):2522-9.

PMID:
15752839
22.

Functional variation of HIV-1 Rev Response Element in a longitudinally studied cohort.

Phuphuakrat A, Paris RM, Nittayaphan S, Louisirirotchanakul S, Auewarakul P.

J Med Virol. 2005 Mar;75(3):367-73.

PMID:
15648073
23.

Changes in HIV prevalence among young Thai men as defined by hepatitis C co-infection as a marker for mode of transmission.

Chanbancherd P, Paris RM, Torugsa K, Myint KS, Sangkharomya S, Brown AE.

AIDS. 2004 Nov 19;18(17):2339-41.

PMID:
15577552
24.

High frequency of HIV-1 and hepatitis C co-infection among young Thai men: evidence for a changing pattern of HIV transmission in Thailand.

Chanbancherd P, Paris RM, Torugsa K, de Souza M, Khin-Saw-Aye-Myint, Chitpong A, Brown AE.

Southeast Asian J Trop Med Public Health. 2003 Sep;34(3):580-2.

PMID:
15115132
25.

Weighing in on type 2 diabetes in the military: characteristics of U.S. military personnel at entry who develop type 2 diabetes.

Paris RM, Bedno SA, Krauss MR, Keep LW, Rubertone MV.

Diabetes Care. 2001 Nov;24(11):1894-8.

PMID:
11679453
26.

[Effect of lipid normalizers (clofibrate and procetofene) on chylomicron metabolism in rats].

Bourdeaux AM, Paris RM.

Arch Int Physiol Biochim. 1980 Feb;88(1):75-84. French.

PMID:
6155886

Supplemental Content

Loading ...
Support Center